Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zuberitamab in lupus nephritis
ChiCTR2500098368Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Mar 2025
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hlx01 in lupus nephritis (LN) and systemic lupus erythematosus (SLE), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Proportion of complete renal response patients. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
hlx01
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2500098368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098368.